Key Highlights

  • argenx agreed to acquire the remaining shares of Unnatural Products, Inc., in which it already holds a minority stake, in a transaction valued at up to approximately $1.15 billion.
  • The upfront payment is $550 million in cash on hand, with up to $595 million more payable on achievement of specified development and regulatory milestones.
  • The target adds a macrocyclic peptide discovery engine to argenx's antibody engineering capabilities, with the potential for oral and long-acting medicines.
  • Both boards have approved the transaction, and closing is expected by the end of 2026, subject to customary conditions.

argenx (NASDAQ:ARGX), the immunology innovation company headquartered in Amsterdam, has agreed to acquire the remaining shares of Unnatural Products, Inc. (UNP), a Santa Cruz, California biotechnology company focused on macrocyclic peptides. The announcement, dated 9 November 2026, would bring a peptide discovery platform into argenx's existing antibody-based business. argenx already holds a minority stake in UNP and has worked with the company for more than two years, which the companies cite as the basis for the transaction.

Deal structure and payment terms

The agreement values UNP at up to approximately $1.15 billion, combining an upfront payment with later milestone-based amounts. argenx will pay $550 million in cash on hand at closing. The remaining consideration of up to $595 million depends on the achievement of specified development and regulatory milestones, so the full amount will only be paid if UNP's programs reach those stages. Both companies' boards have approved the transaction, and closing is expected by the end of 2026, subject to customary closing conditions.

Morgan Stanley & Co. LLC is serving as exclusive financial adviser to argenx, with DLA Piper LLP acting as its legal adviser. Latham & Watkins LLP is representing UNP. The structure places a large share of the consideration behind future events, which means a meaningful part of the financial exposure will depend on scientific and regulatory progress rather than on the price paid at signing.

Scientific rationale and operating model

UNP has developed a discovery platform for macrocyclic peptides, a class of molecules that can address protein targets that are difficult to reach with conventional drugs. The company combines parallel experimentation with Machine Learning to work through the chemistry challenges involved in designing these compounds. Its founders are macrocycle researchers whose academic work examined how natural macrocycles function, and UNP is building a portfolio aimed at high-value targets that have proven hard to drug.

Under the agreement, UNP's team will remain in Santa Cruz, and that site will serve as argenx's home for peptide discovery. UNP will continue to lead discovery work within a strategic framework agreed with argenx, while argenx will Supply clinical development and commercialization capabilities to move candidates toward patients. The model separates discovery from later-stage execution. argenx's existing portfolio includes the first approved antibody fragment targeting the neonatal Fc receptor, and the companies say peptides could enable oral and long-acting medicines alongside that work.

Risks and open questions

The announcement includes forward-looking statements and identifies several uncertainties. Milestone payments depend on scientific and regulatory outcomes that cannot be guaranteed, and the full consideration may never be paid. Completion is subject to closing conditions, and the companies acknowledge that the definitive agreement could be terminated before closing.

Integration presents practical questions as well. argenx must combine a discovery platform developed by a smaller biotechnology company with its own clinical and commercial operations while preserving UNP's team and scientific culture. The announcement does not provide Revenue forecasts for the acquired programs or the expected accounting effect on argenx's reported results, so the financial impact of the deal remains to be seen as details emerge.

Final Word

The Acquisition gives argenx access to a macrocyclic peptide platform alongside its antibody engineering work, at a total price that combines a $550 million upfront payment with contingent amounts. The effect on the company's pipeline and financial statements will become clearer after closing, expected by the end of 2026, and as UNP reports progress on its discovery programs. Future filings and announcements from both companies will show how the arrangement develops.